Cargando…

Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster

Detalles Bibliográficos
Autores principales:	Marcotte, Harold, Hammarström, Lennart, Pan-Hammarström, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395412/ https://www.ncbi.nlm.nih.gov/pubmed/35995763 http://dx.doi.org/10.1038/s41392-022-01146-0

Ejemplares similares

Omicron variant: a booster depending on infection histories
por: Wang, Jiayu, et al.
Publicado: (2023)

Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant
por: Zuo, Fanglei, et al.
Publicado: (2022)

Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients—a perspective
por: Hammarström, Lennart, et al.
Publicado: (2020)

Antibody therapy for COVID-19
por: Hammarström, Lennart, et al.
Publicado: (2021)

SARS-CoV-2 variant Omicron: currently the most complete “escapee” from neutralization by antibodies and vaccines
por: Li, Maochen, et al.
Publicado: (2022)

Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant
por: Zhao, Xin, et al.
Publicado: (2022)

Passive Immunization: Toward Magic Bullets
por: Marcotte, Harold, et al.
Publicado: (2015)

Could Beta variant containing COVID-19 booster vaccines tackle Omicron variants?
por: Jin, Pengfei, et al.
Publicado: (2023)

Boosting with variant-matched vaccines: an opportunity to win the race against Omicron
por: Wang, Jiayu, et al.
Publicado: (2022)

Co-Expression of Anti-Rotavirus Proteins (Llama VHH Antibody Fragments) in Lactobacillus: Development and Functionality of Vectors Containing Two Expression Cassettes in Tandem
por: Günaydın, Gökçe, et al.
Publicado: (2014)

A booster with SARS-CoV-2 vaccines: protection against Omicron infection
por: Hu, Yuehong, et al.
Publicado: (2022)

The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022
por: Sridhar, Saranya, et al.
Publicado: (2022)

Omicron variant and booster COVID-19 vaccines
por: Burki, Talha Khan
Publicado: (2022)

COVID vaccine booster doses for omicron variants
por: Burki, Talha
Publicado: (2022)

Structural insights into the Omicron spike trimer: tackling the challenges of continuously evolving SARS-CoV-2 variants
por: Ou, Junxian, et al.
Publicado: (2022)

Hallmarks of Cancers: Primary Antibody Deficiency Versus Other Inborn Errors of Immunity
por: Abolhassani, Hassan, et al.
Publicado: (2021)

Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies
por: Pant, Neha, et al.
Publicado: (2007)

Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant
por: Sitaras, Ioannis, et al.
Publicado: (2022)

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
por: Yu, Xiaoqi, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Lactobacillus delivery of bioactive interleukin-22
por: Lin, Yin, et al.
Publicado: (2017)

Unique DNA Repair Gene Variations and Potential Associations with the Primary Antibody Deficiency Syndromes IgAD and CVID
por: Offer, Steven M., et al.
Publicado: (2010)

Clinical implications and considerations for evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines
por: Bean, Lora J. H., et al.
Publicado: (2017)

Fusion of the mouse IgG1 Fc domain to the VHH fragment (ARP1) enhances protection in a mouse model of rotavirus
por: Günaydın, Gökçe, et al.
Publicado: (2016)

A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern
por: Schultz, Bárbara M., et al.
Publicado: (2022)

An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
por: Luo, Deyan, et al.
Publicado: (2022)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant
por: Schubert, Maren, et al.
Publicado: (2022)

Hide and seek with SARS-CoV-2: spike receptor-binding domain-specific memory B cells still recognize Omicron variant
por: Odak, Ivan, et al.
Publicado: (2022)

Evaluation of cross-neutralizing antibodies in children infected with omicron sub-variants
por: Peng, Weiyu, et al.
Publicado: (2023)

SARS-CoV-2 variants: a new challenge to convalescent serum and mRNA vaccine neutralization efficiency
por: Li, Maochen, et al.
Publicado: (2021)

VIPPID: a gene-specific single nucleotide variant pathogenicity prediction tool for primary immunodeficiency diseases
por: Fang, Mingyan, et al.
Publicado: (2022)

Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection
por: Pendharkar, Sonal, et al.
Publicado: (2015)

Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees
por: YangYang, et al.
Publicado: (2022)

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
por: Li, Gen, et al.
Publicado: (2022)

19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern
por: García-Vega, Melissa, et al.
Publicado: (2023)

SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread
por: Wang, Xinling, et al.
Publicado: (2023)

Third booster vaccination and stopping the Omicron, a new variant of concern
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

Third booster vaccination and stopping the Omicron, a new variant of concern
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

In situ gastrointestinal protection against anthrax edema toxin by single-chain antibody fragment producing lactobacilli
por: Andersen, Kasper Krogh, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ospdevdgs9kdgmi5q3unvte3ji